Press Releases

BIOMS MEDICAL TO PRESENT CLINICAL AND MANUFACTURING INFORMATION AT TIDES® CONFERENCE 2006

Edmonton, Alberta, April 26, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Dr. Mark Krantz, Vice President Scientific Affairs, BioMS Medical, along with Dr. Marie-Hélène Brichard, Head of Process Development of Lonza Braine S.A., Belgium will present at the TIDES® Conference 2006 in Carlsbad, California.

WHEN: Tuesday, May 2, 2006 at 10:10 am (Pacific Time)
WHERE: La Costa Resort and Spa - Carlsbad, CA

Dr. Krantz will be presenting general clinical trial information on BioMS Medical’s lead product, MBP8298, for the treatment of multiple sclerosis (MS). Dr. Brichard will be presenting information on the CMC (the chemistry, manufacturing, and controls) development of MBP8298.

MBP8298 is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). MBP8298 has been developed for the treatment of MS and BioMS is currently enrolling patients across Canada, the U.K. and Sweden in its pivotal phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS).

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.